Matthew Schwee

Cooley previously advised Impact Analytics, a leader in artificial intelligence (AI)-native innovation and the only provider of an end-to-end platform for pricing, merchandising and supply chain on the close of its Series D funding round led by Blue Cloud Ventures.

Cooley advised Atsena Therapeutics, a clinical-stage gene therapy company developing best-in-class treatments for the reversal or prevention of blindness from inherited retinal diseases, on the close of its oversubscribed $150 million Series C financing.

Cooley advised Abnormal Security, the leader in AI-native human behavior security, on its $250 million Series D financing at a $5.1 billion valuation.

Cooley advised Sword Health, pioneer of the AI Care platform, which uses artificial intelligence to power the delivery of care, on its raise of $130 million in a mix of primary and secondary sales.

Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.